Drugs / JLP-1207
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02494349 | Aug → Nov 2015 | benign prostatic hyperplasia, overactive bladder | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02447367 | Jul → Sep 2015 | benign prostatic hyperplasia, overactive bladder | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JLP-1207 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02494349 ↗ |
| Route | Oral | “Fasted followed by fed in period 1, the subjects will receive an oral pill of JLP-1207 under fasted condition.” NCT02447367 ↗ |